

Special Issue

Drug Safety and Effectiveness in the Real World

Message from the Guest Editors

Drug safety evaluation is an important issue throughout the lifecycle of drug product development, and real-world evidence plays an essential role. Randomized controlled trials are considered to provide the highest level of scientific evidence for clinical therapies.

However, inappropriate usage of medications, and long-term and rare adverse effects are not easily evaluated in traditional clinical trials. Therefore, clinicians must evaluate the benefits and risks and make decisions regarding therapies from various sources. In general, using real-world data with appropriate study designs, suitable epidemiological methods and well-controlled bias and confounding effects, real-world evidence can be generated. Such evidence can also bridge the gap from randomized controlled trials to demonstrate the efficacy and safety of medications or medical products in the real world. Authors are invited to submit original and review articles on drug safety, therapeutic effectiveness and the economic burden of all common therapies which can be published in the Special Issue 'Drug Safety and Effectiveness in the Real World' of *Pharmacoepidemiology*.

Guest Editors

Dr. Li-Ting Kao

Dr. Yu-Tien Chang

Dr. Ke-Ting Pan

Deadline for manuscript submissions

closed (30 November 2023)



Pharmacoepidemiology

an Open Access Journal
by MDPI

Indexed in Scopus
Tracked for Impact Factor



mdpi.com/si/124810

Pharmacoepidemiology
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmacoepidemiology@mdpi.com

[mdpi.com/journal/
pharmacoepidemiology](https://mdpi.com/journal/pharmacoepidemiology)





Pharmacoepidemiology

an Open Access Journal
by MDPI

Indexed in Scopus
Tracked for Impact Factor



[mdpi.com/journal/
pharmacoepidemiology](https://mdpi.com/journal/pharmacoepidemiology)



About the Journal

Message from the Editor-in-Chief

We are very proud to launch this new, international, peer-reviewed, and open access journal. The main aim of *Pharmacoepidemiology* is to publish novel and up-to-date research findings, reviews, and communications on the beneficial effects of drugs as well as their potential adverse effects on humans through epidemiological studies conducted in the real world on large populations.

All researchers working in the pharmacoepidemiologic field—such as epidemiologists, clinical researchers, pharmacologists, clinicians, and biostatisticians—are welcome to contribute to *Pharmacoepidemiology*.

Editor-in-Chief

Dr. Carlotta Franchi

Laboratory of Pharmacoepidemiology and Human Nutrition,
Department of Health Policy, Istituto di Ricerche Farmacologiche Mario
Negri IRCCS, Milan, Italy

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within ESCI (Web of Science), Scopus and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.3 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the second half of 2025).